Literature DB >> 3189792

Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high-performance liquid chromatography.

E W Holmes1.   

Abstract

The status of the oxidative metabolism of L-tryptophan is usually evaluated by the determination of tryptophan metabolites in serum or urine and/or the activities of various oxidative enzymes in tissues. I have developed assays for serum kynurenine and hepatic tryptophan dioxygenase (TDO) activity based on the determination of kynurenine (KYN) by isocratic, reverse phase HPLC with spectrophotometric detection at 365 nm. Sample pretreatment prior to HPLC requires little more than perchloric acid precipitation of serum or a TDO incubation mixture. The analytical recovery for the serum assay was 101 +/- 2%, while the run-to-run coefficient of variation at normal KYN levels was approximately 8%. Serum KYN levels in 40 apparently healthy fasting humans were normally distributed and ranged from 0.27 to 0.69 microgram/ml (mean +/- SD: 0.47 +/- 0.1). Serum KYN in predialysis specimens from a group of 20 patients with chronic renal failure demonstrated a highly significant increase (mean +/- SD: 0.83 +/- 0.35 microgram/ml; P less than 0.001) as compared to the reference population. It is possible that such an increase might contribute to the pathophysiology of the uremic state. The analytical recovery of KYN from TDO incubation mixtures was approximately 90%. There was no evidence for the onward metabolism of KYN during the assay of whole liver homogenates. The mean (+/- SD) TDO activity of rat liver homogenates preincubated with ascorbate and hematin was 2.3 +/- 0.8 mumol/h/g wet wt (30 degrees C). The sensitivity, specificity, and convenience of these two methods suggest that they are suitable for routine use in the investigation of the biology and pathology of oxidative tryptophan metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3189792     DOI: 10.1016/0003-2697(88)90478-2

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  16 in total

1.  Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.

Authors:  D Pawlak; K Pawlak; J Malyszko; M Mysliwiec; W Buczko
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro.

Authors:  Claudia Di Serio; Andrea Cozzi; Ilaria Angeli; Laura Doria; Isabella Micucci; Silvia Pellerito; Patrizia Mirone; Giulio Masotti; Flavio Moroni; Francesca Tarantini
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

3.  Inhibition of Large Neutral Amino Acid Transporters Suppresses Kynurenic Acid Production Via Inhibition of Kynurenine Uptake in Rodent Brain.

Authors:  Airi Sekine; Yusuke Kuroki; Tomomi Urata; Noriyuki Mori; Tsutomu Fukuwatari
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

4.  Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid.

Authors:  J F Reinhard
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

5.  Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.

Authors:  M P Heyes; C Y Chen; E O Major; K Saito
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

6.  The activation of the kynurenine pathway in a rat model with renovascular hypertension.

Authors:  Jacek Bartosiewicz; Tomasz Kaminski; Krystyna Pawlak; Malgorzata Karbowska; Anna Tankiewicz-Kwedlo; Dariusz Pawlak
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

7.  Activation of the Serotonin Pathway is Associated with Poor Outcome in COPD Exacerbation: Results of a Long-Term Cohort Study.

Authors:  Marc A Meier; Manuel Ottiger; Alaadin Vögeli; Christian Steuer; Luca Bernasconi; Robert Thomann; Mirjam Christ-Crain; Christoph Henzen; Claus Hoess; Werner Zimmerli; Andreas Huber; Beat Mueller; Philipp Schuetz
Journal:  Lung       Date:  2017-04-22       Impact factor: 2.584

8.  4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells).

Authors:  K Saito; C Y Chen; M Masana; J S Crowley; S P Markey; M P Heyes
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

9.  Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain.

Authors:  G Ceresoli-Borroni; A Rassoulpour; H-Q Wu; P Guidetti; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

10.  Diclofenac increases the accumulation of kynurenate following tryptophan pretreatment in the rat: a possible factor contributing to its antihyperalgesic effect.

Authors:  Stephen R Edwards; Laurence E Mather
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.